A Randomized Controlled Trial of Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in HIV-Infected Individuals

Steven Safren, Conall O'Cleirigh, Judy Y. Tan, Sudha R. Raminani, Laura C. Reilly, Michael W. Otto, Kenneth H. Mayer

Research output: Contribution to journalArticle

231 Citations (Scopus)

Abstract

Objective: To evaluate cognitive-behavioral therapy to enhance medication adherence and reduce depression (CBT-AD) in individuals with HIV. Design: A two arm, randomized, controlled, cross-over trial comparing CBT-AD to enhanced treatment as usual only (ETAU). ETAU, which both groups received, included a single-session intervention for adherence and a letter to the patient's provider documenting her or his continued depression. The intervention group also received 10 to 12 sessions of CBT-AD. Main Outcome Measures: Adherence to antiretroviral therapy as assessed by Medication Event Monitoring Systems (MEMs) and depression as assessed by blinded structured evaluation. Results: At the acute outcome assessment (3-months), those who received CBT-AD evidenced significantly greater improvements in medication adherence and depression relative to the comparison group. Those who were originally assigned to the comparison group who chose to cross over to CBT-AD showed similar improvements in both depression and adherence outcomes. Treatment gains for those in the intervention group were generally maintained at 6-and 12-month follow-up assessments. By the end of the follow-up period, those originally assigned CBT-AD demonstrated improvements in plasma HIV RNA concentrations, though these differences did not emerge before the cross-over, and hence there were not between-groups differences. Conclusions: CBT-AD is a potentially efficacious approach for individuals with HIV struggling with depression and adherence. Replication and extension in larger efficacy trials are needed.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalHealth Psychology
Volume28
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Cognitive Therapy
Randomized Controlled Trials
HIV
Depression
Medication Adherence
Outcome Assessment (Health Care)
Therapeutics
Cross-Over Studies
RNA

Keywords

  • adherence
  • cognitive behavioral therapy
  • HIV

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Applied Psychology

Cite this

A Randomized Controlled Trial of Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in HIV-Infected Individuals. / Safren, Steven; O'Cleirigh, Conall; Tan, Judy Y.; Raminani, Sudha R.; Reilly, Laura C.; Otto, Michael W.; Mayer, Kenneth H.

In: Health Psychology, Vol. 28, No. 1, 01.2009, p. 1-10.

Research output: Contribution to journalArticle

Safren, Steven ; O'Cleirigh, Conall ; Tan, Judy Y. ; Raminani, Sudha R. ; Reilly, Laura C. ; Otto, Michael W. ; Mayer, Kenneth H. / A Randomized Controlled Trial of Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in HIV-Infected Individuals. In: Health Psychology. 2009 ; Vol. 28, No. 1. pp. 1-10.
@article{5f90d1347714433d9b601007546b353d,
title = "A Randomized Controlled Trial of Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in HIV-Infected Individuals",
abstract = "Objective: To evaluate cognitive-behavioral therapy to enhance medication adherence and reduce depression (CBT-AD) in individuals with HIV. Design: A two arm, randomized, controlled, cross-over trial comparing CBT-AD to enhanced treatment as usual only (ETAU). ETAU, which both groups received, included a single-session intervention for adherence and a letter to the patient's provider documenting her or his continued depression. The intervention group also received 10 to 12 sessions of CBT-AD. Main Outcome Measures: Adherence to antiretroviral therapy as assessed by Medication Event Monitoring Systems (MEMs) and depression as assessed by blinded structured evaluation. Results: At the acute outcome assessment (3-months), those who received CBT-AD evidenced significantly greater improvements in medication adherence and depression relative to the comparison group. Those who were originally assigned to the comparison group who chose to cross over to CBT-AD showed similar improvements in both depression and adherence outcomes. Treatment gains for those in the intervention group were generally maintained at 6-and 12-month follow-up assessments. By the end of the follow-up period, those originally assigned CBT-AD demonstrated improvements in plasma HIV RNA concentrations, though these differences did not emerge before the cross-over, and hence there were not between-groups differences. Conclusions: CBT-AD is a potentially efficacious approach for individuals with HIV struggling with depression and adherence. Replication and extension in larger efficacy trials are needed.",
keywords = "adherence, cognitive behavioral therapy, HIV",
author = "Steven Safren and Conall O'Cleirigh and Tan, {Judy Y.} and Raminani, {Sudha R.} and Reilly, {Laura C.} and Otto, {Michael W.} and Mayer, {Kenneth H.}",
year = "2009",
month = "1",
doi = "10.1037/a0012715",
language = "English (US)",
volume = "28",
pages = "1--10",
journal = "Health Psychology",
issn = "0278-6133",
publisher = "American Psychological Association Inc.",
number = "1",

}

TY - JOUR

T1 - A Randomized Controlled Trial of Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in HIV-Infected Individuals

AU - Safren, Steven

AU - O'Cleirigh, Conall

AU - Tan, Judy Y.

AU - Raminani, Sudha R.

AU - Reilly, Laura C.

AU - Otto, Michael W.

AU - Mayer, Kenneth H.

PY - 2009/1

Y1 - 2009/1

N2 - Objective: To evaluate cognitive-behavioral therapy to enhance medication adherence and reduce depression (CBT-AD) in individuals with HIV. Design: A two arm, randomized, controlled, cross-over trial comparing CBT-AD to enhanced treatment as usual only (ETAU). ETAU, which both groups received, included a single-session intervention for adherence and a letter to the patient's provider documenting her or his continued depression. The intervention group also received 10 to 12 sessions of CBT-AD. Main Outcome Measures: Adherence to antiretroviral therapy as assessed by Medication Event Monitoring Systems (MEMs) and depression as assessed by blinded structured evaluation. Results: At the acute outcome assessment (3-months), those who received CBT-AD evidenced significantly greater improvements in medication adherence and depression relative to the comparison group. Those who were originally assigned to the comparison group who chose to cross over to CBT-AD showed similar improvements in both depression and adherence outcomes. Treatment gains for those in the intervention group were generally maintained at 6-and 12-month follow-up assessments. By the end of the follow-up period, those originally assigned CBT-AD demonstrated improvements in plasma HIV RNA concentrations, though these differences did not emerge before the cross-over, and hence there were not between-groups differences. Conclusions: CBT-AD is a potentially efficacious approach for individuals with HIV struggling with depression and adherence. Replication and extension in larger efficacy trials are needed.

AB - Objective: To evaluate cognitive-behavioral therapy to enhance medication adherence and reduce depression (CBT-AD) in individuals with HIV. Design: A two arm, randomized, controlled, cross-over trial comparing CBT-AD to enhanced treatment as usual only (ETAU). ETAU, which both groups received, included a single-session intervention for adherence and a letter to the patient's provider documenting her or his continued depression. The intervention group also received 10 to 12 sessions of CBT-AD. Main Outcome Measures: Adherence to antiretroviral therapy as assessed by Medication Event Monitoring Systems (MEMs) and depression as assessed by blinded structured evaluation. Results: At the acute outcome assessment (3-months), those who received CBT-AD evidenced significantly greater improvements in medication adherence and depression relative to the comparison group. Those who were originally assigned to the comparison group who chose to cross over to CBT-AD showed similar improvements in both depression and adherence outcomes. Treatment gains for those in the intervention group were generally maintained at 6-and 12-month follow-up assessments. By the end of the follow-up period, those originally assigned CBT-AD demonstrated improvements in plasma HIV RNA concentrations, though these differences did not emerge before the cross-over, and hence there were not between-groups differences. Conclusions: CBT-AD is a potentially efficacious approach for individuals with HIV struggling with depression and adherence. Replication and extension in larger efficacy trials are needed.

KW - adherence

KW - cognitive behavioral therapy

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=58849135865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849135865&partnerID=8YFLogxK

U2 - 10.1037/a0012715

DO - 10.1037/a0012715

M3 - Article

VL - 28

SP - 1

EP - 10

JO - Health Psychology

JF - Health Psychology

SN - 0278-6133

IS - 1

ER -